Market Overview:
The global myelofibrosis treatment market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of myelofibrosis, rising awareness about myelofibrosis treatments, and technological advancements in the field of myelofibrosis treatment. The global myelofibrosis treatment market can be segmented on the basis of type into blood transfusion, chemotherapy, androgen therapy, and others. On the basis of application, the market can be segmented into hospitals, clinics, bone marrow transplant centers (BMTCs), and others. The regional segments for this market are North America (U.S., Canada), Latin America (Mexico & Brazil), Europe (Germany & U.K.), Asia Pacific (China & India) and Middle East Africa(GCC Countries).
Product Definition:
Myelofibrosis Treatment is a medical procedure that is used to treat Myelofibrosis. Myelofibrosis Treatment can help to improve the symptoms of the disease and may also slow down or stop the progression of the disease.
Blood Transfusion:
Blood transfusion is the process of replacing blood that was lost due to injury or disease. It is a common procedure and has been around for quite some time. The first recorded instance of blood transfusion was in 847 B.C., by the Greek physician Hippocrates, who described it as a treatment for acute bleeding.
Chemotherapy:
Chemotherapy is the use of drugs or chemical substances to treat cancer. The most common types of cancers that require chemotherapy are lung, breast, colorectal, and stomach. Chemotherapy used for myelofibrosis can be divided into two categories: Non-Cytotoxic and Cytotoxic Chemoinheritance (CCN-CPH). CCL4/5 is a protein produced by white blood cells in response to infection.
Application Insights:
The market is segmented by application into hospitals, clinics, and bone marrow transplant centers. Hospitals held the largest share in 2017 owing to the availability of advanced healthcare facilities and infrastructure at major cities across various countries. Moreover, these centers offer treatment for myelofibrosis with a combination of chemotherapy drugs that are not available at clinics or bone marrow transplant centers.
Clinics are anticipated to witness lucrative growth over the forecast period due to increasing awareness about early diagnosis and availability of less-invasive procedures for treating patients with myelofibrosis. For instance, Mylotarg (or MELAFIND) is an FDA-approved drug used for treating patients diagnosed with acute myelogenous leukemia (AML), chronic lymphocytic leukemia (CLL), or polycythemia vera who have not responded well to other treatments such as chemotherapy or stem cell transplants.
Regional Analysis:
North America dominated the global myelofibrosis treatment market in 2017. This can be attributed to the presence of key players, availability of novel drug therapies, and high healthcare expenditure in this region. Moreover, increasing cases of blood cancer are also contributing toward regional growth. For instance, according to the American Cancer Society Inc., approximately 1 million new cases were diagnosed with leukemia or lymphoma in U.S., during 2016-2017 period.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to rising awareness about MFR and its treatment options among patients as well as physicians.
Key players operating in Asia Pacific include Novartis AG; Pfizer Inc.; Merck & Co., Inc.
Growth Factors:
- Increasing incidence of myelofibrosis
- Growing awareness about myelofibrosis and its treatment options
- Rising demand for better and more effective treatment options for myelofibrosis
- Availability of novel, targeted therapies for the treatment of myelofibrosis
- Growing investment in research and development for the development of new treatments for myelofibrosis
Scope Of The Report
Report Attributes
Report Details
Report Title
Myelofibrosis Treatment Market Research Report
By Type
Blood Transfusion, Chemotherapy, Androgen Therapy
By Application
Hospitals, Clinics, Bone Marrow Transplant Centers
By Companies
Incyte, Novartis, Celgene, Mylan Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly, Taro Pharmaceuticals, AllCells, Lonza Group, ATCC
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
200
Number of Tables & Figures
140
Customization Available
Yes, the report can be customized as per your need.
Global Myelofibrosis Treatment Market Report Segments:
The global Myelofibrosis Treatment market is segmented on the basis of:
Types
Blood Transfusion, Chemotherapy, Androgen Therapy
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Bone Marrow Transplant Centers
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Incyte
- Novartis
- Celgene
- Mylan Pharmaceuticals
- Bristol-Myers Squibb
- Eli Lilly
- Taro Pharmaceuticals
- AllCells
- Lonza Group
- ATCC
Highlights of The Myelofibrosis Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Blood Transfusion
- Chemotherapy
- Androgen Therapy
- By Application:
- Hospitals
- Clinics
- Bone Marrow Transplant Centers
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Myelofibrosis Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Myelofibrosis is a rare and serious bone marrow disorder that causes the body to produce too few white blood cells. This can lead to infections, difficulty breathing, and even death. Treatment typically includes chemotherapy and radiation therapy.
Some of the major companies in the myelofibrosis treatment market are Incyte, Novartis, Celgene, Mylan Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly, Taro Pharmaceuticals, AllCells, Lonza Group, ATCC.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Myelofibrosis Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Myelofibrosis Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Myelofibrosis Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Myelofibrosis Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Myelofibrosis Treatment Market Size & Forecast, 2020-2028
4.5.1 Myelofibrosis Treatment Market Size and Y-o-Y Growth
4.5.2 Myelofibrosis Treatment Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Blood Transfusion
5.2.2 Chemotherapy
5.2.3 Androgen Therapy
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Bone Marrow Transplant Centers
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Myelofibrosis Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Myelofibrosis Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Blood Transfusion
9.6.2 Chemotherapy
9.6.3 Androgen Therapy
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.10.3 Bone Marrow Transplant Centers
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Blood Transfusion
10.6.2 Chemotherapy
10.6.3 Androgen Therapy
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.10.3 Bone Marrow Transplant Centers
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Blood Transfusion
11.6.2 Chemotherapy
11.6.3 Androgen Therapy
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.10.3 Bone Marrow Transplant Centers
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Blood Transfusion
12.6.2 Chemotherapy
12.6.3 Androgen Therapy
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.10.3 Bone Marrow Transplant Centers
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Blood Transfusion
13.6.2 Chemotherapy
13.6.3 Androgen Therapy
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.10.3 Bone Marrow Transplant Centers
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Myelofibrosis Treatment Market: Competitive Dashboard
14.2 Global Myelofibrosis Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Incyte
14.3.2 Novartis
14.3.3 Celgene
14.3.4 Mylan Pharmaceuticals
14.3.5 Bristol-Myers Squibb
14.3.6 Eli Lilly
14.3.7 Taro Pharmaceuticals
14.3.8 AllCells
14.3.9 Lonza Group
14.3.10 ATCC
